A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

Exclusion Criteria

• •Anti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal therapy within 4 weeks prior to Day 1
• •Prior treatment with MUC16 targeted therapy (e.g., oregovomab \[OvaRex\] or abagovomab) including DMUC5754A
• •Prior treatment with a monomethyl auristatin E (MMAE)-containing antibody-drug conjugate (ADC)
• •Palliative radiation to bone metastases within 2 weeks prior to Day 1
• •Prior radiation to lung fields
• •Major surgical procedure within 4 weeks prior to Day 1
• •Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (including human immunodeficiency virus \[HIV\] and atypical mycobacterial disease but excluding fungal infections of the nail beds) at study enrollment or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1, Day 1
• •Evidence of significant uncontrolled concomitant diseases, such as ocular toxicities, diabetes, cardiovascular disease; nervous system, renal, hepatic, endocrine, or gastrointestinal disorders; autoimmune disease, or a serious non-healing wound or fracture
• •Clinically significant pulmonary symptoms and signs, any active pulmonary or respiratory infection at enrollment, pulmonary infiltrates on screening CT scan of the chest that are associated with symptoms (including dyspnea), resting or exercise arterial oxygen saturation (SpO2) less than (\<) 90 percent (%), requirement for supplementary oxygen at rest or exercise (either continuously or intermittently), moderate (40%-60% predicted) or severe (\<40% predicted) decreased diffusing capacity for carbon monoxide (DLCO) or mild (\>60% \</= lower limit of normal \[LLN\]% predicted) decrease with clinically significant symptoms
• •Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
• •Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix, squamous carcinoma of the skin, adequately controlled limited basal cell skin cancer, or synchronous primary endometrial cancer or prior primary endometrial cancer if protocol criteria are met
• •Untreated or active central nervous system (CNS) metastases. Participants with a history of treated CNS metastases may be eligible
• •Current Grade greater than (\>) 1 toxicity (except alopecia and anorexia) from prior therapy or Grade \>1 neuropathy from any cause
• •History of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
• •Pregnancy or breastfeeding
• •Inability to comply with study and follow-up procedures
• •Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the participants at high risk from treatment complications